Japan’s top drugmaker on Friday reported an annual loss for the first time in its history after agreeing to pay $2.4 billion to settle U.S. lawsuits over cancer claims regarding its Actos diabetes drug.
Japan Today
HINTS
drugmaker reported an annual loss
agreeing to pay $2.4 billion to settle lawsuits over claims regarding its drug